A synthetic glucocorticoid with anti-inflammatory properties.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Fluprednisolone. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fluprednisolone. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fluprednisolone. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Fluprednisolone. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fluprednisolone. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Fluprednisolone. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Fluprednisolone. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fluprednisolone. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluprednisolone. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluprednisolone. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluprednisolone. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluprednisolone. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Fluprednisolone. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluprednisolone. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Fluprednisolone. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluprednisolone. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluprednisolone. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluprednisolone. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Fluprednisolone. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluprednisolone. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluprednisolone. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluprednisolone. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluprednisolone. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluprednisolone. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Fluprednisolone. |
| Cladribine | Fluprednisolone may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Fluprednisolone. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Fluprednisolone. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Fluprednisolone. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Fluprednisolone. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Fluprednisolone. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Fluprednisolone. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Fluprednisolone. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Fluprednisolone. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Fluprednisolone. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Fluprednisolone. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Vinorelbine is combined with Fluprednisolone. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluprednisolone. |
| Sorafenib | The risk or severity of adverse effects can be increased when Sorafenib is combined with Fluprednisolone. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Fluprednisolone. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Fluprednisolone. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Fluprednisolone. |
| Teniposide | The risk or severity of adverse effects can be increased when Teniposide is combined with Fluprednisolone. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Fluprednisolone. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Fluprednisolone. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Fluprednisolone. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Fluprednisolone. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Fluprednisolone. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluprednisolone. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Fluprednisolone. |
| Vincristine | The risk or severity of adverse effects can be increased when Vincristine is combined with Fluprednisolone. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fluprednisolone. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fluprednisolone. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Fluprednisolone. |
| Methotrexate | The risk or severity of adverse effects can be increased when Methotrexate is combined with Fluprednisolone. |
| Vinblastine | The risk or severity of adverse effects can be increased when Vinblastine is combined with Fluprednisolone. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Fluprednisolone. |
| Imatinib | The risk or severity of adverse effects can be increased when Imatinib is combined with Fluprednisolone. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Fluprednisolone. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Fluprednisolone. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluprednisolone. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fluprednisolone. |
| Irinotecan | The risk or severity of adverse effects can be increased when Irinotecan is combined with Fluprednisolone. |
| Etoposide | The risk or severity of adverse effects can be increased when Etoposide is combined with Fluprednisolone. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Fluprednisolone. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Fluprednisolone. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Fluprednisolone. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Fluprednisolone. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Fluprednisolone. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Fluprednisolone. |
| Cytarabine | The risk or severity of adverse effects can be increased when Cytarabine is combined with Fluprednisolone. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Fluprednisolone. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Doxorubicin is combined with Fluprednisolone. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Fluprednisolone. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluprednisolone. |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Fluprednisolone. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Fluprednisolone. |
| Thalidomide | The risk or severity of adverse effects can be increased when Thalidomide is combined with Fluprednisolone. |
| Melphalan | The risk or severity of adverse effects can be increased when Melphalan is combined with Fluprednisolone. |
| Fludarabine | The risk or severity of adverse effects can be increased when Fludarabine is combined with Fluprednisolone. |
| Flucytosine | The risk or severity of adverse effects can be increased when Flucytosine is combined with Fluprednisolone. |
| Capecitabine | The risk or severity of adverse effects can be increased when Capecitabine is combined with Fluprednisolone. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Fluprednisolone. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fluprednisolone. |
| Idarubicin | The risk or severity of adverse effects can be increased when Idarubicin is combined with Fluprednisolone. |
| Ifosfamide | The risk or severity of adverse effects can be increased when Ifosfamide is combined with Fluprednisolone. |
| Estramustine | The risk or severity of adverse effects can be increased when Estramustine is combined with Fluprednisolone. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Fluprednisolone. |
| Lomustine | The risk or severity of adverse effects can be increased when Lomustine is combined with Fluprednisolone. |
| Docetaxel | The risk or severity of adverse effects can be increased when Docetaxel is combined with Fluprednisolone. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Fluprednisolone. |
| Decitabine | The risk or severity of adverse effects can be increased when Decitabine is combined with Fluprednisolone. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Fluprednisolone. |
| Stepronin | The risk or severity of adverse effects can be increased when Stepronin is combined with Fluprednisolone. |
| Hydroxychloroquine | The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Fluprednisolone. |
| Castanospermine | The risk or severity of adverse effects can be increased when Castanospermine is combined with Fluprednisolone. |
| Vorinostat | The risk or severity of adverse effects can be increased when Vorinostat is combined with Fluprednisolone. |
| 2-Methoxyethanol | The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Fluprednisolone. |
| Brequinar | The risk or severity of adverse effects can be increased when Brequinar is combined with Fluprednisolone. |
| Pirfenidone | The risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluprednisolone. |